FDA approves irinotecan as first-line therapy for colorectal cancer

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2000年 / 14卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：652 / +
页数：2
相关论文
共 50 条
  • [41] Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer
    Glimelius, B
    Ristamäki, R
    Kjaer, M
    Pfeiffer, P
    Skovsgaard, T
    Tveit, KM
    Linné, T
    Frödin, JE
    Boussard, B
    Oulid-Aïssa, D
    Pyrhönen, S
    ANNALS OF ONCOLOGY, 2002, 13 (12) : 1868 - 1873
  • [42] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Okagawa, Yutaka
    Murase, Kazuyuki
    Takada, Kohichi
    Kawano, Yutaka
    Iyama, Satoshi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Mizuguchi, Toru
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 587 - 594
  • [43] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    Zarate, R.
    Rodriguez, J.
    Bandres, E.
    Patino-Garcia, A.
    Ponz-Sarvise, M.
    Viudez, A.
    Ramirez, N.
    Bitarte, N.
    Chopitea, A.
    Gacia-Foncillas, J.
    BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 987 - 994
  • [44] Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer
    Cartwright, Thomas
    Kuefler, Paul
    Cohn, Allen
    Hyman, William
    Berger, Maury
    Richards, Donald
    Vukelja, Svetislava
    Nugent, John E.
    Ruxer, Robert L., Jr.
    Boehm, Kristi A.
    Asmar, Lina
    CLINICAL COLORECTAL CANCER, 2008, 7 (06) : 390 - 397
  • [45] Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis
    Liang Xiao-bo
    Hou Sheng-huai
    Li Yao-ping
    Wang Li-chun
    Zhang Xin
    Yang Jun
    CHINESE MEDICAL JOURNAL, 2010, 123 (22) : 3314 - 3318
  • [46] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    R Zarate
    J Rodríguez
    E Bandres
    A Patiño-Garcia
    M Ponz-Sarvise
    A Viudez
    N Ramirez
    N Bitarte
    A Chopitea
    J Gacía-Foncillas
    British Journal of Cancer, 2010, 102 : 987 - 994
  • [47] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Yasushi Sato
    Hiroyuki Ohnuma
    Masahiro Hirakawa
    Minoru Takahashi
    Takahiro Osuga
    Yutaka Okagawa
    Kazuyuki Murase
    Kohichi Takada
    Yutaka Kawano
    Satoshi Iyama
    Tsuyoshi Hayashi
    Tsutomu Sato
    Koji Miyanishi
    Rishu Takimoto
    Masayoshi Kobune
    Kenji Okita
    Toru Mizuguchi
    Tomohisa Furuhata
    Koichi Hirata
    Junji Kato
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 587 - 594
  • [48] Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer.
    Schmitt, C
    Levy-Piedbois, C
    Frappé, M
    Durand-Zaleski, I
    Gruia, G
    Alakl, M
    Rougier, P
    ANNALS OF ONCOLOGY, 2000, 11 : 47 - 47
  • [49] Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II
    Garcia Alfonso, Pilar
    Munoz Martin, Andres
    Alvarez Suarez, Sonsoles
    Blanco Codeidido, Monserrat
    Mondejar Solis, Rebeca
    Tapia Rico, Gonzalo
    Lopez Martin, Pilar
    Martin, Miguel
    ONKOLOGIE, 2013, 36 (06): : 363 - 367
  • [50] FDA approves first CAR T therapy
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (10) : 669 - 669
12345